CA-WIND-RIVER
26.4.2022 12:02:24 CEST | Business Wire | Press release
Wind River® , a global leader in delivering software for intelligent systems, today announced it has been selected by BAE Systems to support technology demonstration work as part of the Tempest future combat air system program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005579/en/
“We are honored be working with BAE Systems,” said Avijit Sinha, chief product officer, Wind River. “The selection of our industry-leading technology demonstrates continuing Wind River leadership in safety-critical real-time software solutions for avionics.”
Wind River software is in use by more than 360 customers over 600 safety programs in more than 100 civilian, military, and space systems, delivering innovative technology that solves real business problems.
BAE Systems will be using the VxWorks 653 platform, a part of Wind River Studio , and associated DO-178C DAL B safety certification evidence packages, and AdaCore GNAT Pro Assurance as part of ongoing technology demonstration project work in support of the program. Wind River Studio is a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems.
The aerospace and defense market has high urgency to build the most complete intelligent systems, according to recent research. True compute on the far edge and the ability to emulate and simulate in real time are two of the most important intelligent systems characteristics for future success. In this industry, the ability to make accurate, quick decisions in high-risk scenarios is critical, and artificial intelligence is becoming an increasingly important investment.1
Team Tempest is a co-funded technology initiative launched by the Royal Air Force Rapid Capabilities Office and U.K. industry partners with the aim of advancing combat air technology. BAE Systems is one of the founding members of Team Tempest.
The Tempest future combat air system will incorporate advanced technical capabilities including AI, which creates opportunities such as the ability to fly manned or unmanned or to use swarming technology to control drones. Tempest is currently in the concept and assessment phase. Initial operating capability is expected in the mid-2030s.
Leveraging a safety-critical platform with COTS safety certification packages can reduce technical program risk. Proven in the most challenging safety-critical applications, VxWorks 653 makes it easier and more cost-effective for technology suppliers to meet the stringent safety certification requirements of EN 50128, IEC 61508, ISO 26262, DO-178C, and ED-12C.
About Wind River
Wind River is a global leader in delivering software for intelligent systems. The company’s technology has been powering the safest, most secure devices in the world since 1981 and is found in billions of products. Wind River offers a comprehensive portfolio, supported by world-class global professional services and support and a broad partner ecosystem. Wind River software and expertise are accelerating digital transformation of mission-critical intelligent systems that will increasingly demand greater compute and AI capabilities while delivering the highest levels of security, safety, and reliability. To learn more, visit Wind River at www.windriver.com .
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005579/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom